Cimetidine
- Generic Name
- Cimetidine
- Brand Names
- Good Sense Heartburn Relief, Tagamet
- Drug Type
- Small Molecule
- Chemical Formula
- C10H16N6S
- CAS Number
- 51481-61-9
- Unique Ingredient Identifier
- 80061L1WGD
- Background
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
- Indication
Cimetidine is indicated to reduce gastric acid secretion and to treat the following disease states: duodenal ulcers, non-malignant gastric ulcers, gastroesophageal reflux disease, and pathological hypersecretion associated with Zollinger-Ellison Syndrome, systemic mastocytosis, and multiple endocrine adenomas. It is indicated for prophylaxis of recurrent gastric or duodenal ulcers, as adjunctive therapy in the management of cystic fibrosis in children, and to treat NSAID induced lesions and gastrointestinal symptoms.
- Associated Conditions
- Cystic Fibrosis (CF), Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Gastrointestinal Symptoms, Heartburn, Active Duodenal ulcer, Benign gastric ulcers, Develop NSAID-induced gastric ulcers, Recurrent Ulcers, Duodenal and Gastric
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
- Conditions
- Gastroesophageal Reflux Disease (GERD)Community-acquired Pneumonia
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 4238504
- Registration Number
- NCT02555852
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
Drug-drug Interaction Study of CHF5993 With Cimetidine
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 25
- Registration Number
- NCT02287272
- Locations
- 🇧🇪
Life Science Services SGS Belgium NV, Antwerp, Belgium
Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BI 1060469 high doseDrug: BI 1060469 low dose
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02202512
- Locations
- 🇩🇪
1333.43.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02172417
Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 343
- Registration Number
- NCT02157376
- Locations
- 🇨🇳
Research Site, Zhanjiang, China
High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
- Conditions
- Bleeding Peptic Ulcer
- Interventions
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239
- Registration Number
- NCT01757275
- Locations
- 🇨🇳
Research Site, Xian, China
Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 14
- Registration Number
- NCT01536249
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Cimetidine Biowaivers
- Conditions
- Healthy
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 25
- Registration Number
- NCT01256879
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
Class 3 Biowaivers
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 48
- Registration Number
- NCT01010698
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
- Conditions
- Generalized Anxiety Disorder
- Interventions
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00800280
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.